FimmCyte secures 1 million CHF investment for Non-Hormonal Endometriosis treatment

FimmCyte, an innovative biotech company dedicated to women's health, has announced its latest achievement in improving endometriosis treatment. Securing a CHF 1 million convertible loan from the UZH Life Sciences Fund (LSF), the startup reinforces its leadership in addressing this condition.

FimmCyte, a spin-off from the University of Zürich and the University Hospital Zürich, was established in 2022 by Valentina Vongrad and Mohaned Shilaih. This pre-clinical stage biotech firm, stemming from the Lab of Prof. Brigitte Leener, focuses on treatments for women’s health and beyond. Using tailored biotechnological methods, FimmCyte reprograms the immune system to address target diseases at their core.

The company's flagship project involves developing the first disease-modifying treatment for endometriosis, with plans to progress into IND-enabling activities. FimmCyte's impressive growth has attracted support from prestigious funding bodies such as BaseLaunch, the BioInnovation Institute, and the USZ health innovation hub, as well as securing non-dilutive funding from Innosuisse and the Gebert Rüf Foundation.

FimmCyte participated in Venture Leaders Biotech in 2022 as well as won the last stage of the Venture Kick program in the same year.

"Venture Leaders gave us the chance to be immersed in the Boston biotech ecosystem and learn about the US investment and collaboration mindset, a highly recommended experience," commented Mohaned Shilaih, Co-Founder of Fimmcyte.


FimmCyte's Co-Founders Mohaned Shilaih and Valentina Vongrad